United States · Biotechnology startup
United States · Invivyd
Invivyd develops antibodies to transcend the limitations of the human immune system and fight against viral infections.
Funding reportedLast round: Series C
What company datasets say Invivyd raised
Funding, as reported
Reported in all$466Min dollars
Rounds3
Last roundSeries C
Last round dateApr 2021
Investors listed15
Founders and team
From Invivyd's own website and the SEC filings it signed: 12 on the team.
- David HeringChief Executive Officer and Directori
- Marc EliaChairman and Chief Executive Officer
- Timothy LeeChief Commercial Officer
- Ellie HershbergerChief Development Officeri
- Fred DriscollInterim Chief Financial Officeri
- Jill AndersenChief Legal Officer and Corporate Secretaryi
- Rebecca DaboraChief Technology and Manufacturing Officeri
- Ajay RoyanLead Independent Director
- Ian SheffieldDirector
- Kevin F. McLaughlinDirector
- Terrance McGuireDirector
- Tamsin BerryDirector
On the board, as filediChristine A. LindenboomClive A. MeanwellMichael S. WyzgaTerry McGuireTom Heyman
Biotechnology in United States
Startups like it
- SojournixWaltham · founded 2016Raised
- Receptor Life SciencesSeattle · founded 2017Raised
- Attune PharmaceuticalsNew York · founded 2018Raised
AbbVieNorth Chicago · founded 2012
GrailMenlo Park · founded 2015
EQRxCambridge · founded 2019- Cerevel TherapeuticsBoston · founded 2018
Royalty PharmaNew York · founded 1996
Is this your company?
Add your raise, your deck and your story, and put Invivyd in front of investors. Or tell us what we have wrong.